Robert Flisiak

21.6k total citations · 2 hit papers
364 papers, 7.8k citations indexed

About

Robert Flisiak is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Robert Flisiak has authored 364 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 232 papers in Hepatology, 230 papers in Epidemiology and 69 papers in Infectious Diseases. Recurrent topics in Robert Flisiak's work include Hepatitis C virus research (193 papers), Liver Disease Diagnosis and Treatment (171 papers) and Hepatitis B Virus Studies (144 papers). Robert Flisiak is often cited by papers focused on Hepatitis C virus research (193 papers), Liver Disease Diagnosis and Treatment (171 papers) and Hepatitis B Virus Studies (144 papers). Robert Flisiak collaborates with scholars based in Poland, United States and Germany. Robert Flisiak's co-authors include Jerzy Jaroszewicz, Patrick Marcellin, D Prokopowicz, Anna Parfieniuk‐Kowerda, Edward Gane, Thomas Berg, Dorota Zarębska‐Michaluk, Michael Fried, Teerha Piratvisuth and Małgorzata Pawłowska and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Robert Flisiak

332 papers receiving 7.6k citations

Hit Papers

Peginterferon Alfa-2a, La... 2005 2026 2012 2019 2005 2014 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
    2005 1.1k citations Robert Flisiak et al. profile →
  2. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
    2014 592 citations Robert Flisiak et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robert Flisiak 5.4k 5.4k 1.5k 828 514 364 7.8k
Hiroshi Yotsuyanagi 3.3k 0.6× 3.0k 0.6× 1.1k 0.7× 1.1k 1.3× 473 0.9× 232 5.5k
Ramsey Cheung 5.5k 1.0× 4.4k 0.8× 634 0.4× 600 0.7× 460 0.9× 211 7.4k
Kosh Agarwal 8.2k 1.5× 8.2k 1.5× 1.2k 0.8× 412 0.5× 423 0.8× 248 10.0k
Nicola Coppola 3.9k 0.7× 3.6k 0.7× 1.3k 0.9× 405 0.5× 170 0.3× 291 5.9k
Markus Cornberg 6.9k 1.3× 7.1k 1.3× 1.8k 1.2× 721 0.9× 2.3k 4.6× 399 10.8k
Wan‐Long Chuang 8.3k 1.5× 8.5k 1.6× 733 0.5× 939 1.1× 553 1.1× 513 11.1k
Arthur Y. Kim 2.7k 0.5× 3.3k 0.6× 1.2k 0.8× 390 0.5× 1.1k 2.1× 121 4.9k
David Wong 3.8k 0.7× 3.7k 0.7× 569 0.4× 440 0.5× 890 1.7× 126 5.6k
Doris B. Strader 5.2k 1.0× 5.0k 0.9× 609 0.4× 373 0.5× 180 0.4× 37 6.4k
Chihiro Morishima 3.2k 0.6× 3.2k 0.6× 819 0.5× 640 0.8× 747 1.5× 82 6.0k

Countries citing papers authored by Robert Flisiak

Since Specialization
Citations

This map shows the geographic impact of Robert Flisiak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Flisiak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Flisiak more than expected).

Fields of papers citing papers by Robert Flisiak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Flisiak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Flisiak. The network helps show where Robert Flisiak may publish in the future.

Co-authorship network of co-authors of Robert Flisiak

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Flisiak. A scholar is included among the top collaborators of Robert Flisiak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Flisiak. Robert Flisiak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Antczak, Adam, Adam Barczyk, Robert Flisiak, et al.. (2025). RSV prevention in adults: consensus of experts of Polish scientific societies. Family Medicine & Primary Care Review. 27(3). 353–359.
2.
Zarębska‐Michaluk, Dorota, Piotr Tyszko, Birutė Strukčinskienė, et al.. (2025). The burden of viral hepatitis infection and mortality: Findings from a population-based study in Poland over 2009–2023. Clinical and Experimental Hepatology. 11(2). 137–146.
3.
Rzymski, Piotr, et al.. (2025). Hepatic involvement in major respiratory viral infections. Clinical and Experimental Hepatology. 11(2). 121–128.
4.
Flisiak, Robert, et al.. (2025). Steatotic liver disease in patients treated for chronic hepatitis B. Polskie Archiwum Medycyny Wewnętrznej. 135(3). 3 indexed citations
5.
Grygorczuk, Sambor, Piotr Czupryna, Anna Parfieniuk‐Kowerda, et al.. (2025). The Role of Chemotactic Cytokines in Tick-Borne Encephalitis. Cells. 14(7). 490–490.
6.
Toczyłowski, Kacper, et al.. (2024). Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Consequences and Anti-Inflammatory Treatment . Medical Science Monitor. 30. e944052–e944052. 2 indexed citations
7.
Zarębska‐Michaluk, Dorota, Michał Kukla, Dorota Dybowska, et al.. (2024). Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices. Pharmacological Reports. 76(5). 1114–1129. 1 indexed citations
8.
Piekarska, Anna, Hanna Berak, Włodzimierz Mazur, et al.. (2024). Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide. Clinical and Experimental Hepatology. 10(3). 165–169.
9.
Jaroszewicz, Jerzy, Dorota Zarębska‐Michaluk, Magdalena Rogalska, et al.. (2024). Association between Liver Damage and Disease Progression Markers with Mortality Risk and Mechanical Ventilation in Hospitalized COVID-19 Patients: A Nationwide Retrospective SARSTer Study. Viruses. 16(10). 1530–1530. 2 indexed citations
10.
Flisiak, Robert, Dorota Zarębska‐Michaluk, Hanna Berak, et al.. (2024). Treatment with Sofosbuvir/Velpatasvir of the most difficult to cure HCV-infected population. Polskie Archiwum Medycyny Wewnętrznej. 134(2). 2 indexed citations
11.
Parfieniuk‐Kowerda, Anna, et al.. (2024). Cannabinoids and the endocannabinoid system in liver diseases. Clinical and Experimental Hepatology. 10(4). 211–217.
12.
Zarębska‐Michaluk, Dorota, Olga Tronina, Anna Piekarska, et al.. (2024). Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination. BMC Medicine. 22(1). 486–486. 1 indexed citations
13.
14.
Zarębska‐Michaluk, Dorota, et al.. (2024). Impact of the COVID-19 and War Migration on HIV/AIDS Epidemiology in Poland. Journal of Clinical Medicine. 13(14). 4106–4106. 1 indexed citations
15.
Tronina, Olga, Dorota Zarębska‐Michaluk, Dorota Dybowska, et al.. (2023). Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens. Viruses. 15(3). 677–677. 3 indexed citations
16.
Tronina, Olga, Dorota Zarębska‐Michaluk, Beata Lorenc, et al.. (2023). Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure. Clinical and Experimental Hepatology. 9(4). 320–334. 1 indexed citations
17.
Flisiak, Robert, Dorota Zarębska‐Michaluk, Hanna Berak, et al.. (2023). Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals. Clinical and Experimental Hepatology. 9(3). 193–201. 4 indexed citations
18.
Rzymski, Piotr, Marcin Drąg, Robert Flisiak, et al.. (2021). The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines. 9(2). 109–109. 95 indexed citations
19.
20.
Flisiak, Robert, et al.. (2016). New therapeutic options for HCV in Central Europe. Clinical and Experimental Hepatology. 1(1). 7–11. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroshi Yotsuyanagi Breakdown of academic impact, for papers by Ramsey Cheung Breakdown of academic impact, for papers by Kosh Agarwal Breakdown of academic impact, for papers by Nicola Coppola Breakdown of academic impact, for papers by Markus Cornberg Breakdown of academic impact, for papers by Wan‐Long Chuang Breakdown of academic impact, for papers by Arthur Y. Kim Breakdown of academic impact, for papers by David Wong Breakdown of academic impact, for papers by Doris B. Strader Breakdown of academic impact, for papers by Chihiro Morishima
Rankless by CCL
2026